Navigation Links
Cellular Biomedicine Group Announces Appointment of Corporate Controller

PALO ALTO, Calif., June 6, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Gene Hsiao as Corporate Controller.

Mr. Hsiao has over 20 years of experience in corporate finance and management for U.S. listed public companies, including a pharmaceutical company. Mr. Hsiao is a U.S. Certified Public Accountant.

Andrew Chan , Chief Financial Officer of Cellular Biomedicine Group, stated, "We are delighted to have Mr. Hsiao join the Company. His wealth of control, accounting and compliance knowledge will be invaluable to our management team".

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064

SOURCE Cellular Biomedicine Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics Announces Commercial Launch of iCellĀ® Neurons for Neuroscience Drug Discovery
2. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
3. Proteins shine a brighter light on cellular processes
4. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
5. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
6. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
7. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
8. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
9. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
10. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
11. Cellular Therapy and Cord Blood 2013 Market Report
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnlineā€™s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
Breaking Biology News(10 mins):